For patients with schizophrenia and breast cancer, adjuvant radiation therapy may not be preferable
the ONA take:
According to a new study published in The American Journal of Surgery, researchers have found that for patients with schizophrenia and breast cancer, initial radical surgery without adjuvant radiation therapy may be preferred. For the study, researchers sought to investigate how patients with schizophrenia who later develop breast cancer handle treatment with adjuvant radiation.
Researchers identified 40 patients with schizophrenia who later developed breast cancer and were candidates for adjuvant radiation therapy from the national computer database of the Department of Veterans Affairs. Results showed clinicians decided to offer adjuvant radiation therapy in 35 of 40 patients, but only offered it to 22 patients. Of those 22 patients, 23% refused treatment with adjuvant radiation therapy.
The findings suggest that patients with both schizophrenia and breast cancer do not fully comprehend their diseases. In addition, patients with schizophrenia are often non-compliant with recommended standard therapies, especially those that depend upon adjuvant radiation therapy. Therefore, the research suggest that strategies that involve conserving the breast may not be the best option, and initial radical surgery without the use of radiation may be better for the patient.
According to the National Institute of Mental Health, patients with schizophrenia often lack the ability to understand information and use that information to make decisions.
For patients with schizophrenia and breast cancer, initial radical surgery without radiation therapy preferred.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|